Xeris Biopharma (NASDAQ:XERS) versus Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) Head-To-Head Review

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) and Xeris Biopharma (NASDAQ:XERS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Earnings and Valuation

This table compares Recordati Industria Chimica E Farmaceutica and Xeris Biopharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recordati Industria Chimica E Farmaceutica	$2.53 billion	5.33	$450.70 million	$3.17	20.64
Xeris Biopharma	$203.07 million	6.20	-$54.84 million	($0.10)	-75.90

Recordati Industria Chimica E Farmaceutica has higher revenue and earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Recordati Industria Chimica E Farmaceutica, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Recordati Industria Chimica E Farmaceutica and Xeris Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Recordati Industria Chimica E Farmaceutica	N/A	N/A	N/A
Xeris Biopharma	-5.88%	N/A	-4.66%

Institutional & Insider Ownership

42.8% of Xeris Biopharma shares are owned by institutional investors. 6.5% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Recordati Industria Chimica E Farmaceutica has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Recordati Industria Chimica E Farmaceutica and Xeris Biopharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recordati Industria Chimica E Farmaceutica	0	0	0	1	4.00
Xeris Biopharma	1	2	5	0	2.50

Xeris Biopharma has a consensus target price of $9.58, suggesting a potential upside of 26.26%. Given Xeris Biopharma’s higher probable upside, analysts clearly believe Xeris Biopharma is more favorable than Recordati Industria Chimica E Farmaceutica.

Summary

Recordati Industria Chimica E Farmaceutica beats Xeris Biopharma on 8 of the 14 factors compared between the two stocks.

About Recordati Industria Chimica E Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.